Yazar "Özel, Gökçe" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim
    Öğe
    Olfactory acuity based on Brief Smell Identification Test (BSIT R) in migraine patients with and without aura: A cross-sectional, controlled study
    (Elsevier Sci Ltd, 2022) Kandemir, Süheyla; Pamuk, A. Erim; Habipoğlu, Yasin ; Özel, Gökçe; Muluk, Nuray Bayar; Kılıç, Rahmi
    Objective: The aim of this study was to evaluate olfactory acuity in migraine patients with and without aura (MwA and MwoA) Material and methods: The study included 30 MwA patients, 30 MwoA patients, and 30 ageand gender-matched controls. Demographic features and odor-related symptoms (osmophobia, odor offensiveness, and odor-triggered attack status) were noted. Olfactory acuity was measured using the Brief Smell Identification Test (BSIT (R)), a 12-item derivative of the University of Pennsylvania Smell Identification Test (UPSIT (R)). BSIT (R) scores were compared between the migraine patients and controls. Results: The mean BSIT (R) score did not differ significantly between the MwA patients (8.7 +/- 0.9) and MwoA (9.17 +/- 0.9) patients (P = 0.094); however, the mean score in the control group was higher (10.4 +/- 0.6) than in the MwA and MwoA patients (P < 0.001). The mean BSIT (R) score did not differ significantly between patients with and without odor-triggered migraine attacks (9 +/- 0.9 and 8.8 +/- 0.8, respectively) (P = 0.4). Osmophobia and odor-triggered attacks were more common in the MwA patients than in the MwoA patients (odor-triggered attacks: 66% vs. 40% [P = 0.04]; osmophobia: 76.6% vs. 60% [P = 0.16]) Conclusion: Olfactory acuity is lower during attack-free periods in migraine patients, as compared to controls. Migraine aura status does not affect olfactory acuity. Odor-triggered attacks, osmophobia, and offensive odors between attacks were more common in the MwA patients than in the MwoA patients. (c) 2021 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights reserved.
  • [ X ]
    Öğe
    Olfactory acuity based on Brief Smell Identification Test (BSIT?) in migraine patients with and without aura: A cross-sectional, controlled study
    (Elsevier Ireland Ltd, 2022) Kandemir, Süheyla; Pamuk, A. Erim; Habipoğlu, Yasin; Özel, Gökçe; Bayar Muluk, Nuray; Kılıç, Rahmi
    Objective: The aim of this study was to evaluate olfactory acuity in migraine patients with and without aura (MwA and MwoA) Material and methods: The study included 30 MwA patients, 30 MwoA patients, and 30 age- and gender-matched controls. Demographic features and odor-related symptoms (osmophobia, odor offensiveness, and odor-triggered attack status) were noted. Olfactory acuity was measured using the Brief Smell Identification Test (BSIT®), a 12-item derivative of the University of Pennsylvania Smell Identification Test (UPSIT®). BSIT® scores were compared between the migraine patients and controls. Results: The mean BSIT® score did not differ significantly between the MwA patients (8.7 ± 0.9) and MwoA (9.17 ± 0.9) patients (P = 0.094); however, the mean score in the control group was higher (10.4 ± 0.6) than in the MwA and MwoA patients (P < 0.001). The mean BSIT® score did not differ significantly between patients with and without odor-triggered migraine attacks (9 ± 0.9 and 8.8 ± 0.8, respectively) (P = 0.4). Osmophobia and odor-triggered attacks were more common in the MwA patients than in the MwoA patients (odor-triggered attacks: 66% vs. 40% [P = 0.04]; osmophobia: 76.6% vs. 60% [P = 0.16]) Conclusion: Olfactory acuity is lower during attack-free periods in migraine patients, as compared to controls. Migraine aura status does not affect olfactory acuity. Odor-triggered attacks, osmophobia, and offensive odors between attacks were more common in the MwA patients than in the MwoA patients. © 2021
  • Küçük Resim
    Öğe
    The Efficacy of Gabapentin+ Dexamethasone for Postoperative Analgesia Following Septoplasty: A Prospective Randomized Placebo-Controlled Tria
    (Sage Publications Inc, 2023) Kandemir, Süheyla; Pamuk, A. Erim; Özel, Gökçe; Gencay, Işın; Kılıç, Rahmi
    Aims: This study aimed to compare the efficacy of gabapentin, dexamethasone, and gabapentin + dexamethasone for pain control after septoplasty. Materials and Methods: This prospective randomized trial included 120 patients that underwent septoplasty and were randomly divided into 4 groups: group G (preoperative gabapentin 600 mg p.o.); group D (intraoperative dexamethasone 8 mg i.v.); group GD (preoperative gabapentin 600 mg p.o. + intraoperative dexamethasone 8 mg i.v.); group C (placebo control). Results: The median VAS score was significantly lower in groups G and GD at 1, 2, 4, 6, 12, and 24 hours postsurgery than in group C (P < .008 for all). The median VAS score was significantly lower in group D than in group C at 1, 2, and 4 hours postsurgery (P < .008 for all). There weren't any significant differences in the VAS score between groups D, G, and GD at any time point. Groups G, D, and GD had a significantly lower frequency of rescue analgesic use than group C; however, there were no differences between groups G, GD, and C (P < .001 and P = .108, respectively). Conclusion: Gabapentin, dexamethasone, and gabapentin + dexamethasone are equally more effective analgesics during the first 4 hours postsurgery than placebo. The addition of dexamethasone to gabapentin does not provide extra analgesia. Both gabapentin and gabapentin + dexamethasone have a more prolonged analgesic effect than dexamethasone alone.
  • [ X ]
    Öğe
    The Efficacy of Gabapentin+Dexamethasone for Postoperative Analgesia Following Septoplasty: A Prospective Randomized Placebo-Controlled Trial
    (SAGE Publications Inc., 2023) Kandemir, Süheyla; Pamuk, A.Erim; Özel, Gökçe; Gençay, Işın; Kılıç, Rahmi
    Aims: This study aimed to compare the efficacy of gabapentin, dexamethasone, and gabapentin + dexamethasone for pain control after septoplasty. Materials and Methods: This prospective randomized trial included 120 patients that underwent septoplasty and were randomly divided into 4 groups: group G (preoperative gabapentin 600 mg p.o.); group D (intraoperative dexamethasone 8 mg i.v.); group GD (preoperative gabapentin 600 mg p.o. + intraoperative dexamethasone 8 mg i.v.); group C (placebo control). Results: The median VAS score was significantly lower in groups G and GD at 1, 2, 4, 6, 12, and 24 hours postsurgery than in group C (P <.008 for all). The median VAS score was significantly lower in group D than in group C at 1, 2, and 4 hours postsurgery (P <.008 for all). There weren’t any significant differences in the VAS score between groups D, G, and GD at any time point. Groups G, D, and GD had a significantly lower frequency of rescue analgesic use than group C; however, there were no differences between groups G, GD, and C (P <.001 and P =.108, respectively). Conclusion: Gabapentin, dexamethasone, and gabapentin + dexamethasone are equally more effective analgesics during the first 4 hours postsurgery than placebo. The addition of dexamethasone to gabapentin does not provide extra analgesia. Both gabapentin and gabapentin + dexamethasone have a more prolonged analgesic effect than dexamethasone alone. © The Author(s) 2022.